Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension

Rhea-AI Summary

Quantum Genomics announced the presentation of results from its phase III study, FRESH, targeting resistant hypertension, scheduled for November 7, 2022, at the American Heart Association conference in Chicago. This pivotal study involves 515 patients across multiple countries and aims to demonstrate the efficacy and safety of firibastat, a new treatment approach. The results are expected to aid in the submission of regulatory files to authorities in the US and Europe.

Positive

• Successful completion of the FRESH study with 515 patients across Europe, Canada, the USA, and Latin America.
• Presentation at a high-profile AHA conference highlights the importance of the findings.

Negative

• None.

PARIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant hypertension and heart-failure, announces that the presentation of the results of its phase III study, FRESH, in resistant hypertension, are now scheduled to take place on November 7, 2022, at 3:00 pm local time (CT), at a specific "Late-breaking trials" session that the American Heart Association (AHA) will dedicate to resistant hypertension during its annual conference in Chicago (USA).

The annual conference of the AHA is putting resistant hypertension in the spotlight by dedicating a specific "Late-breaking trials" session to this subject: "Resistant hypertension: a pressure cooker"

Bruno Besse, Medical Director of Quantum Genomics, states that:

"By dedicating a specific "Late-breaking trials" session to resistant hypertension, the AHA has decided to highlight the global Public Health challenge which is resistant hypertension, for which there is currently little or no effective therapeutic alternative. Once again this demonstrates the interest of the scientific community for this new therapeutic class, represented by firibastat, used to treat resistant hypertension."

The results of the FRESH study, presented at the AHA conference by Professor Bakris, will constitute a crucial first step towards the submission of a registration file to the American and European authorities. 

The FRESH study is the first pivotal phase III study whose objective is to evaluate the efficacy and safety of firibastat in difficult-to-treat and resistant hypertension. A total of 515 eligible patients with difficult-to-treat or resistant hypertension were randomised in the study in 69 hospitals across Europe, Canada, the United States and Latin America.

Recruitment for the REFRESH study, the second pivotal phase III study to assess efficacy and long-term safety of the once daily formulation of firibastat, is continuing normally.

About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. It is based on research conducted at Paris-Descartes University and on work directed by Dr Catherine Llorens-Cortès at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ Scientific Centre for National Research (CNRS) laboratory). The goal of Quantum Genomics is to develop innovative treatments for difficult-to-treat or even resistant hypertension (hypertension is poorly or inadequately controlled in 30% of patients) and heart failure (one in two patients diagnosed with severe heart failure will die within five years).

Based in New York and Paris, the company is listed on Euronext Growth in Paris (FR0011648971- ALQGC) and trades on the OTCQX Market in the United States (symbol: QNNTF). 
For more information, see www.quantum-genomics.com and please visit our Twitter and LinkedIn sites.

Contact information

Quantum Genomics

contact@quantum-genomics.fr

Edifice Communication (EUROPE)

Media and financial communication quantum-genomics@edifice-communication.com

LifeSci (USA)

Mike Tattory Media communication +1 (646) 751-4362 - mtattory@lifescipublicrelations.com

FAQ

What is the FRESH study presented by Quantum Genomics?

The FRESH study is a phase III clinical trial evaluating the efficacy and safety of firibastat in patients with resistant hypertension, involving 515 participants.

When will Quantum Genomics present the FRESH study results?

The results of the FRESH study are scheduled to be presented on November 7, 2022, at the American Heart Association conference.

What is firibastat, and what condition does it target?

Firibastat is a new medication developed by Quantum Genomics intended to treat resistant hypertension, directly targeting the brain's aminopeptidase A.

How many patients were involved in the FRESH study?

A total of 515 patients with difficult-to-treat or resistant hypertension were randomized in the FRESH study.

What impact could the FRESH study results have on Quantum Genomics?

The results are crucial for the submission of registration files to regulatory authorities in the US and Europe, potentially leading to market approval.